TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06757803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rertrolaminar block
Description: Positioning~The patient is positioned in a lateral decubitus position with the affected side up. The patient's arm on the affected side is placed behind the head. The patient's spine is aligned and the shoulder is elevated to expose the paravertebral space.~\*Ultrasound imaging~A high-frequency linear ultrasound probe (5-12 MHz) is placed in a paramedian sagittal plane at the desired level of block. The probe is oriented so that the transverse processes are visualized on the lateral side of the screen and the vertebral laminae are visualized on the medial side of the screen. The interlaminar space is visualized as a hypoechoic region between the laminae.~\*Needle insertion~A short bevel block needle (20-22 G) is inserted through the skin at the caudal end of the ultrasound probe, aiming cephalad. The needle is advanced under real-time ultrasound guidance until the tip of the needle contacts the lamina. The needle is then slightly withdrawn and the local anesthetic is injected into t

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: * Patient Preparation~* Place the patient in the lateral decubitus position with the side of the block facing up.~* Position the patient's arm so that it is resting comfortably on the operating table.~* Prepare the skin over the block site with an antiseptic solution.~* Sterilely drape the area.~* Ultrasound Imaging~* Place the ultrasound probe in a transverse plane at the level of the desired block.~* Identify the following anatomical landmarks:~* Vertebral body~* Transverse process~* Pleura~* Intercostal space~* Needle Insertion~Use a sterile ultrasound-guided needle. Insert the needle in-plane from a lateral to medial direction, aiming for the apex of the paravertebral space.~The needle should be advanced until it is just beyond the transverse process.~\*Test Aspiration~Aspirate to ensure that the needle is not in a blood vessel.~* Local Anesthetic Injection~* Inject the local anesthetic slowly, aspirating frequently.~* The local anesthetic should be injected int
Study: NCT06757738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-100
Description: CEN inhibitor, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-100
Description: CEN inhibitor, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-100
Description: CEN inhibitor, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-100
Description: CEN inhibitor, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, dosage form - capsules, dosing regimen - QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, dosage form - capsules, dosing regimen - QD
Study: NCT06758245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral and anterior sciatic nerve block
Description: First, in the supine position, the USG probe is placed below the inguinal crease. The femoral nerve is located lateral to the femoral artery, above the iliopsoas muscle. Once the needle tip reaches the nerve, simultaneous nerve stimulation is applied. Patellar movement is observed due to quadriceps muscle contraction upon needle placement. After a negative aspiration test, 20 ml of local anesthetic is injected.For the anterior sciatic block, while the patient was in the supine position, a convex ultrasound (USG) probe was placed transversely approximately 10 cm distal to the inguinal ligament. After visualizing the sciatic nerve as a hyperechoic flat structure, the nerve stimulator was set to 1-1.5 mA, 0.1 ms, and 1 Hz. Using an in-plane technique, the block needle was advanced. Upon reaching the sciatic nerve, when contractions in the calf, foot, or big toe continued at a current of 0.3-0.5 mA, 20 ml of 0.5% bupivacaine was administered following a negative aspiration test.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral and popliteal sciatic nerve block
Description: The ultrasound probe is placed transversely at the popliteal crease. The first structure seen is the popliteal artery. Just above and lateral to the artery, the tibial nerve appears as a hyperechoic, oval, and round structure. After identifying the tibial and peroneal nerves, the probe is moved proximally, and it is observed that the nerves join about 5-10 cm above the popliteal crease. The needle is advanced using an in-plane technique. After obtaining the first sciatic nerve stimulation, 20 cc of 0.5% bupivacaine is injected following a negative aspiration test.
Study: NCT06757686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mousetrap appliance
Description: two mini-implant will be inserted in the palate. then, the mousetrap appliance will be inserted on the mini-implant and activated with power chain.
Study: NCT06757972

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tele Rehab
Description: Tele rehabilitation intervention is 6 months standardized program aimed to provide special rehabilitation services to patients with mobility impairments in rural areas without the need for them to travel to healthcare facility in big cities. The program consists of standard exercises addressing key components of mobility impairments.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Formal Rehab
Description: After formal rehabilitation is completed, some impaired mobility victims re-access services; no attempt will be made to stop the control group from accessing further care, in either a public or private setting. However, physical activity participation will be assured during monthly phone call by a blinded -research assistant. Participants in this group will undergo three assessments at baseline, 6 and 12 months
Study: NCT06757491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation treatment
Description: IBS patients received repetitive transcranial magnetic stimulation at~1 Hz/s for 20 minutes for 2 weeks.
Study: NCT06757296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic SASI
Description: Endoscopic conversion to sleeve gastrectomy to SASI
Study: NCT06756334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AlF-PSMA-N5
Description: Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Study: NCT06108505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus with oats
Description: Subjects will receive 7.5 gr of oats containing Lacticaseibacillus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain oats
Description: Subjects will receive 7.5 gr of plain oats
Study: NCT05471050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Danazol is given at 200mg bid for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol is given at 200mg bid for 12 weeks.
Study: NCT04992494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-Telephone
Description: Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-Video
Description: Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
Study: NCT06440200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group gamed-based activity
Description: Participants in interventional group will play the active-type software with Switch game console which develops by Nintendo company. Team building, cooperation, cohesion, sense of belonging and sense of achieving will be emphasized.
Study: NCT06756334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-DCFPyL
Description: Each subject receive a single intravenous injection of \[18F\]F-DCFPyL, and undergo PET/CT imaging within the specificed time.
Study: NCT05773599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
Study: NCT06756789

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic Roux-en Y Gastric bypass (RYGB)- Conventional approach
Description: The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, standard limb lengths of 75cms BP limb and 125cms Alimentary limb were measured and performed, irrespective of the total bowel length
Study: NCT05316649

Intervention type: OTHER
Intervention: Measurement of external blood loss
Description: Measurement of external blood loss

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Hemoglobin concentration
Description: Serum Hemoglobin concentration
Study: NCT04737889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04718116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group tapentadol 50 mg
Description: patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group tapentadol 75 mg
Description: patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group tramadol 100 mg
Description: patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
Study: NCT06756789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en Y Gastric bypass (RYGB)- Tailored approach
Description: The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, limb lengths are tailored according to the total small bowel length, 1/3rd of the total bowel length is measured and in that 3/8th and 5/8th were kept as BP limb and alimentary limb respectively.
Study: NCT06758349

Intervention type: OTHER
Intervention: General questionnaire
Description: Demographic, medical history, and musical activity data will be collected using a specifically designed questionnaire

Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Questionnaire that evaluate pain and functional limitation during last week, last six months e during the carrier.~The impact of painful symptoms on professional and non-professional activities , during the last week, will be assessed using the QuickDASH scale for the upper limb, the Modified Oswestry Low Back Disability Index for low back pain, and the Neck Disability Index questionnaire for cervico-dorsalgia

Intervention type: OTHER
Intervention: Postural assessment without musical instrument in sitting position
Description: Postural assessment without the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.

Intervention type: OTHER
Intervention: Postural assessment with the instrument in sitting position.
Description: Postural assessment with the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
Study: NCT06758375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose teclistamab
Description: NDMM patients will receive VRd 3x cicles followed by low dose teclistamab.
Study: NCT05107453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery.
Study: NCT05051709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy
Description: First metatarsal distal corrective osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion of First ray
Description: Fusion of first ray with soft tissue procedure
Study: NCT06756516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feldenkrais Method and Core stabilization
Description: Balance exercises from supine lying position using Feldenkrais style, plus core stabilization exercises.
Study: NCT06366087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate Ophthalmic Solution USP, 1%
Description: Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Description: Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
Study: NCT04922138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
Study: NCT05055817

Intervention type: OTHER
Intervention: bloody stool group
Description: bloody stool appear in the hospitalized neonate
Study: NCT05709210

Intervention type: OTHER
Group type: OTHER
Intervention: Recording of smartphone usage data
Description: Recording of smartphone usage data

Intervention type: OTHER
Group type: OTHER
Intervention: Recording of smartphone usage data
Description: Recording of smartphone usage data
Study: NCT06360367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HI-FLY Curriculum
Description: Participants receive the standard HI-FLY Curriculum over 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HI-FLY Curriculum + PortionSize Ed app
Description: Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
Study: NCT05828654

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group Discussions and Semi-structured Interviews
Description: Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training community lay navigators
Description: Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
Study: NCT05280509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
Study: NCT06756516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercises
Description: trunk deep muscles activation and engaging using exercises as bridging, side bridging, plank, side plank and McGill Abdominal